Behavioral function improvement of prefrontal cortex in treated depressed rats by ECT and ketamine

Document Type : Research Paper


1 Department of Physiology, School of Medicine, Shahed Univercity,Tehran, Iran

2 Azad University Central Tehran Branch, Tehran, Iran


Background and Objective: Depression is one of the most prevalent mental disorders. Electroconvulsive Therapy (ECT) is one of the effective methods for treatment of depression. Regarding the stimulatory effect of glutaminergic system on the progression of depression, the effect of ketamine as one of the most important inhibitors of this system has been investigated on the effectiveness of ECT. Given the fundamental role of pre-frontal cortex on changing the mood of depression-related behaviors in depressed patients, the effects of ketamine with ECT on this cortex were taken into account in this study.
Materials and Methods: For this purpose, 50 male rats were used. Animals were randomly divided into five equal groups, and except the control group, the other ones were depressed by CUMS method. Then, three groups of depressed rats were treated in different ways (ECT, ketamine, and combined ECT and ketamine). Finally, behavioral parameters were measured.
Results: The combination of ketamine and ECT could reduce prefrontal depression like behaviors by testing of: sucrose intake increased, the total immobility rate also decreased and open field behaviors increased.
Conclusion: According to this study, the modification of behavioral parameters in rats treated with ECT and ketamine indicates the specific effect of electroconvulsive and ketamine therapy in modifying the mood and depression behaviors and behavioral test are showing the alleviation of depression signs. Electroconvulsive therapy in depressed rats with ketamine injection is recommended.


  1. Sagha F, Malmir H, Saneei P, Milajerdi A, Larijani B, Esmaillzadeh A. Fruit and vegetable consumption and risk of depression : accumulative evidence from an updated systematic review and meta-analysis of epidemiological studies. British Journal of Nutrition 2018; 119(10):1087-1101.
  2. Zou  L, Yeung A , Li Ch, Wei  G X, Chen K W, et al. Effects of Meditative Movements on Major Depressive Disorder : A Systematic Review and Meta-Analysis of Randomized Controlled Trials Journal of Clinical Medicine 2018;1;7(8):195.
  3. Mitchell N D, Baker G B. An update on the role of glutamate in the pathophysiology of depression. Acta Psychiatrica Scandinavica 2010; 122(3):192-210.
  4. Chavez-Castillo M, Victoria N, Nava M, Ortega a. Depression as a Neuroendocrine Disorder : Emerging Neuropsychopharmacological Approaches beyond Monoamines. Advances in Pharmacological Sciences 2019(1):1-20.
  5. Ronald D. Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections,” Dialogues in Clinical Neuroscience 2014; 16(1):11-27.
  6. Ratajczak P, Kus K, Zaprutko T, Szczepański M, Rusowicz S, Nowakowska E. Antidepressant and anxiolytic efficacy of single, chronic and concomitant use of vortioxetine, dapoxetine and fluoxetine in prenatally stressed rats. Acta Neurobiologiae Experimentalis 2019; 79(1):13–24.
  7. Suchet D. Khanzode, Ganesh N. Dakhale, Shruti S. Khanzode, Anand Saoji & R. Palasodkar, “Oxidative damage and major depression : the potential antioxidant action of selective serotonin re-uptake inhibitors Oxidative damage and major depression : the potential antioxidant action of selective serotonin. Redox Report 2003; 8(6):365-70.
  8. Lopresti A L, Maker G L, Hood S D, Drummond P D. A review of peripheral biomarkers in major depression : The potential of in fl ammatory and oxidative stress biomarkers. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2014;48:102-11.
  9. Hillhouse T M, Porter J H. A brief history of the development of antidepressant drugs: From monoamines to glutamateic. Experimental and Clinical Psychopharmacology 2015;23(1):1-21.
  10. Friedman M A, Detweiler-Bedell J B, Leventhal H E, Horne R, Keitner G I, et al. Combined Psychotherapy and Pharmacotherapy for the Treatment of Major Depressive Disorder. Clinical Psychology: Science and Practice 2004; 1(1):47–68.
  11. Fajemiroye J O, Silva D M , Oliveira D M, Costa E A. Treatment of anxiety and depression : medicinal plants in retrospect. Fundamental & Clinical Pharmacology 2016;30(3):198-215.
  12. Kheradmand E, Hajizadeh Moghaddam A, Zare M. Neuroprotective effect of hesperetin and nano-hesperetin on recognition memory impairment and the elevated oxygen stress in rat model of Alzheimer’s disease. Biomedicine & Pharmacotherapy 2018; 97:1096–1101.
  13. Ishola I O, Jacinta A A, Adeyem O O. Cortico-hippocampal memory enhancing activity of hesperetin on scopolamine-induced amnesia in mice : role of antioxidant defense system, cholinergic neurotransmission and expression of BDNF. Metabolic Brain Disease 2019;34(4):979-989.
  14. Antkiewicz-Michaluk L, Wasik A, Mozdzen E, Romanska I, Michaluk J. Antidepressant-like Effect of Tetrahydroisoquinoline Amines in the Animal Model of Depressive Disorder Induced by Repeated Administration of a Low Dose of Reserpine : Behavioral and Neurochemical Studies in the Rat. Neurotoxicity Research 2014;26(1):85-98.
  15. Tanaka Sh,Young J W, Halberstadt A L, Masten V L, Geyer M A. Four factors underlying mouse behavior in an open field. Behavioural Brain Research 2012;233(1):55-61.
  16. Mohammadi M, Parsi B. Anxiety–related Behavioral Alterations Following Repeated Paraoxon Exposure in Rats. Journal of Mazandaran University of Medical Sciences 24(117):116-124.
  17. Walf A A, Frye Ch A. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nature Protocols 2007; 2(2): 322–328.
  18. Luo J, Min S, Wei K, Jun C, Wang B, et al Propofol prevents electroconvulsive-shock- induced memory impairment through regulation of hippocampal synaptic plasticity in a rat model of depression. Neuropsychiatric Disease and Treatment  2014;10:1847-59.
  19. O. Donovan S, Dalton V, Harkin A, and Mcloughlin D M. Effects of brief pulse and ultrabrief pulse electroconvulsive stimulation on rodent brain and behaviour in the corticosterone model of depression 2014;17(9):1477-1486.
  20. Ikram M, Muhammad T, Rehman Sh Ur, Khan A, Gi Jo M, et al. Hesperetin Confers Neuroprotection by Regulating Nrf2/TLR4/NF-κB Signaling in an Aβ Mouse Model. Molecular Neurobiology 2019;56(9):6293-6309.
  21. Zahedi E, Sanaei Rad A, Khalili M, Esmail Jamaat, et al. The effect of electroconvulsive therapy on the levels of oxidative stress factors in the prefrontal cortex of depressed rats 2018; 6(2):27-31.
  22. Zhang F, Luo J, Min S, Ren L, Qin P. Propofol alleviates electroconvulsive shock-induced memory impairment by modulating proBDNF/mBDNF ratio in depressive rats. Brain Research 2016;1642: 43–50.
  23. Valvassori S S, Varela R B, Quevedo J. Animal Models of Mood Disorders: Focus on Bipolar Disorder and Depression. Second Edi. Elsevier Inc 2017; 991-1001.